RESEARCH PAPER

Natural Biopolymer-Based Nanoformulations for the Management of Arthritis: Advances, Challenges, and Translational Perspectives

Sachin A. Nitave[1], Sachin S. Mali[2], Rahul S. Adnaik[3], Utkarsha R. Yadav[2], Pradip S. Pawde[4], Sayali S. Patil[1*]

[1] Dr. J. J. Magdum Trust's Anil Alias Pintu Magdum Memorial Pharmacy College, Dharangutti, Kolhapur, India
[2] Bharati Vidyapeeth College of Pharmacy, Kolhapur-416013, India.
Emails: sachinmali143@gmail.com; utkarshay3018@gmail.com
[3] Dept. of Pharmacology, Anandi Pharmacy College, Kolhapur, Maharashtra, India
[4] S. R. Institute of Pharmacy, Udgir, Maharashtra, India – 413517
[1*] Corresponding Author: Sayali S. Patil, Lecturer, Dr. J. J. Magdum Trusts, Anil Alias Pintu Magdum Memorial Pharmacy College, Dharangutti. Address: Tal. Shirol, Dist. Kolhapur, 416101, Maharashtra, India.
Email: patilsayali389@gmail.com. ORCID ID: 0009-0002-5128-1722

Received: 12th Mar, 2026 | **Revised:** 24th Mar, 2026 | **Accepted:** 14th Apr, 2026 | **Available Online:** 30th Apr, 2026

Abstract

Arthritis is a chronic inflammatory disorder characterized by progressive joint degeneration, persistent pain, and functional impairment, posing a major therapeutic challenge worldwide. Although conventional pharmacological treatments such as non-steroidal anti-inflammatory drugs, corticosteroids, and disease-modifying antirheumatic drugs are widely used, their long-term effectiveness is often limited by poor joint specificity, systemic toxicity, and frequent dosing requirements. In recent years, nanotechnology-based drug delivery systems have emerged as promising platforms to overcome these limitations. Among them, natural biopolymer-based nanoformulations have gained considerable attention due to their inherent biocompatibility, biodegradability, and functional versatility. Biopolymers such as chitosan, hyaluronic acid, alginate, gelatin, and cellulose derivatives have been extensively explored as nanocarriers for delivering anti-inflammatory agents, corticosteroids, disease-modifying antirheumatic drugs, and bioactive compounds. These nanoformulations enhance drug localization within inflamed joints, prolong intra-articular residence time, and enable controlled drug release, thereby improving therapeutic efficacy while reducing systemic adverse effects. This review provides a comprehensive overview of the pathophysiology of arthritis, the rationale for biopolymer-based nano-delivery, formulation strategies, therapeutic payloads, preclinical outcomes, and key translational challenges. Future perspectives for clinical application are also discussed.

Keywords

Arthritis; Natural biopolymers; Nanotechnology; Drug delivery systems; Chitosan; Hyaluronic acid

How to cite this article: Nitave SA, Mali SS, Adnaik RS, Yadav UR, Pawde PS, Patil SS. Natural Biopolymer-Based Nanoformulations for the Management of Arthritis: Advances, Challenges, and Translational Perspectives. Int J Drug Deliv Technol. 2026;16(41s): 657-663. DOI: 10.25258/ijddt.16.41s.71

Graphical Abstract



Graphical representation of natural biopolymer-based nanoformulations for arthritis therapy. Drug-loaded biopolymer nanocarriers administered via systemic or intra-articular routes preferentially accumulate in inflamed joint tissues, enabling targeted delivery and sustained drug release. The schematic also highlights major nanoformulation platforms derived from natural biopolymers, including nanoparticles, nanogels, injectable hydrogels, and hybrid composite systems, which collectively enhance therapeutic efficacy while minimizing systemic toxicity.

1. Introduction

Arthritis comprises a group of chronic musculoskeletal disorders that significantly impair quality of life and impose a substantial socioeconomic burden. Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovial inflammation and progressive joint destruction, whereas osteoarthritis (OA) is primarily associated with cartilage degeneration, subchondral bone remodeling, and low-grade inflammation[1,2]. Despite advances in pharmacological therapy, effective long-term management of arthritis remains challenging.

Conventional treatments such as non-steroidal anti-inflammatory drugs, corticosteroids, and disease-modifying antirheumatic drugs provide symptomatic relief but are often associated with systemic adverse effects following prolonged use[3]. Moreover, these therapies frequently fail to achieve sustained drug concentrations at the site of inflammation, resulting in suboptimal therapeutic outcomes. These limitations have stimulated interest in advanced drug delivery systems capable of improving drug localization, reducing dosing frequency, and enhancing therapeutic efficacy.

Nanotechnology-based drug delivery systems offer several advantages, including improved pharmacokinetic profiles, enhanced bioavailability, and targeted drug delivery. Among various nanocarriers, natural biopolymer-based nanoformulations are particularly attractive due to their favorable biological properties, minimal immunogenicity, and ease of functional modification[4]. This review critically evaluates recent progress in natural biopolymer-based nanoformulations for arthritis therapy, with emphasis on formulation design, biological performance, and translational potential.

2. Pathophysiology of Arthritis and Rationale for Targeted Drug Delivery

The pathogenesis of arthritis involves complex interactions among immune cells, synovial fibroblasts, chondrocytes, and inflammatory mediators. In RA, persistent immune activation leads to excessive production of cytokines such as tumor necrosis factor-α, interleukin-1β, and

interleukin-6, resulting in cartilage erosion and bone damage[5]. In OA, mechanical stress and biochemical factors contribute to extracellular matrix degradation and chronic inflammation.

Inflamed joint tissues exhibit increased vascular permeability, altered extracellular matrix composition, and overexpression of surface receptors such as CD44. These pathological features provide opportunities for targeted drug delivery using nano-sized carriers[6]. However, conventional systemic administration often results in insufficient drug accumulation within joints while increasing off-target toxicity.

Nanoformulations can exploit enhanced permeability and retention effects in inflamed tissues, allowing preferential accumulation within arthritic joints. Furthermore, natural biopolymers can be engineered to respond to local stimuli such as pH, enzymatic activity, and oxidative stress, thereby improving site-specific drug release and therapeutic efficacy[7].



Figure 1. Mechanistic illustration of natural biopolymer-based nanoformulation delivery to arthritic joints

Schematic representation of drug-loaded natural biopolymer nanoparticles following administration, demonstrating preferential accumulation in inflamed synovial tissue, receptor-mediated uptake by synoviocytes and macrophages, and sustained intra-articular drug release.

3. Natural Biopolymers Used in Arthritis Nanoformulations

3.1 Chitosan

Chitosan is a naturally derived cationic polysaccharide obtained from chitin. Its biodegradability, bioadhesive nature, and ease of chemical modification make it one of the most extensively investigated biopolymers in drug delivery. The positive surface charge of chitosan nanoparticles facilitates interaction with negatively charged synovial membranes and enhances cellular uptake[8]. Chitosan-based nanoformulations have demonstrated improved drug loading, sustained release, and enhanced anti-inflammatory efficacy in arthritis models[9].

3.2 Hyaluronic Acid

Hyaluronic acid is a naturally occurring glycosaminoglycan abundantly present in synovial fluid and cartilage. Hyaluronic acid-based nanoformulations offer dual functionality by providing joint lubrication and receptor-mediated targeting through CD44 receptors, which are overexpressed in arthritic tissues[10]. These systems exhibit prolonged intra-articular retention and improved therapeutic outcomes.

3.3 Alginate

Alginate is an anionic polysaccharide derived from marine sources and is capable of forming hydrogels and nano-sized carriers under mild conditions. Its injectability and favorable safety profile make alginate particularly suitable for intra-articular drug delivery. Alginate-based nanoformulations have been reported to provide sustained drug release and cartilage-protective effects in osteoarthritis models[11].

Table 1. Natural biopolymers commonly employed in nanoformulations for arthritis therapy

Biopolymer	Source	Key physicochemical features	Therapeutic relevance in arthritis
Chitosan	Chitin (crustacean shells)	Cationic, biodegradable, mucoadhesive	Enhances cellular uptake and pH-responsive drug release
Hyaluronic acid	Synovial fluid, ECM	CD44 receptor affinity, viscoelastic	Joint targeting, lubrication, prolonged retention
Alginate	Brown seaweed	Injectable, gel-forming	Sustained intra-articular drug release
Gelatin	Collagen hydrolysis	Biodegradable, ECM-mimicking	Supports cartilage repair
Cellulose derivatives	Plant biomass	Stable, modifiable	Improves formulation stability



Figure 2. Classification of natural biopolymer nanoformulations used in arthritis therapy

Oerview of nanoformulation types derived from natural biopolymers, including nanoparticles, nanogels, injectable hydrogels, and hybrid composite systems employed for arthritis treatment

4. Nanoformulation Strategies for Arthritis Therapy

Natural biopolymers can be processed into various nano-architectures, including nanoparticles, nanogels, injectable hydrogels, and hybrid composite systems. Nanoparticles offer high surface area and efficient drug encapsulation, while nanogels provide high water content and injectability. Hybrid systems combining multiple biopolymers are designed to enhance mechanical stability, drug loading efficiency, and controlled release behavior. These strategies collectively contribute to improved therapeutic performance compared with conventional formulations[12].

Table 2. Representative natural biopolymer-based nanoformulations investigated for arthritis management

Biopolymer system	Encapsulated drug	Formulation type	Arthritis model	Key outcome	Reference
Chitosan nanoparticles	Methotrexate	Nanoparticles	Rheumatoid arthritis (rat)	Reduced joint inflammation, lower toxicity	[9]

HA-coated nanoparticles	Dexamethasone	Targeted nanoparticles	Osteoarthritis	Prolonged joint retention	[11]
Alginate hydrogel nanoparticles	Diclofenac	Injectable nanogel	Osteoarthritis	Sustained release, cartilage protection	[12]
Chitosan–HA hybrid	Curcumin	Hybrid nanoparticles	RA	Enhanced anti-inflammatory effect	[14]

Table 3. Advantages and limitations of natural biopolymer-based nanoformulations

Aspect	Advantages	Limitations
Biocompatibility	Low toxicity, minimal immune response	Batch variability
Drug delivery	Sustained and localized release	Limited drug loading (some systems)
Manufacturing	Mild processing conditions	Scale-up complexity
Clinical translation	Improved therapeutic index	Regulatory challenges

5. Therapeutic Agents Delivered Using Biopolymer Nanoformulations

A wide range of therapeutic agents have been incorporated into natural biopolymer-based nanoformulations, including non-steroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs, and natural bioactive compounds such as curcumin and resveratrol. Encapsulation within biopolymeric matrices improves solubility, protects drugs from degradation, and minimizes systemic exposure while maintaining effective local concentrations within joints[13].

6. Preclinical Evaluation and Therapeutic Outcomes

Preclinical studies using animal models of arthritis have demonstrated that natural biopolymer-based nanoformulations significantly reduce joint inflammation, suppress pro-inflammatory cytokine expression, and improve cartilage integrity. Compared with conventional formulations, these systems achieve superior therapeutic outcomes at lower doses and with reduced systemic toxicity[14].

7. Translational Challenges and Regulatory Considerations

Despite encouraging preclinical results, clinical translation of biopolymer-based nanoformulations remains limited. Challenges include large-scale manufacturing, batch-to-batch reproducibility, sterilization, long-term safety evaluation, and regulatory approval pathways. Addressing these issues through standardized production protocols and comprehensive toxicological studies is essential for successful clinical application[15].



Figure 3. Translational pathway of biopolymer-based nanoformulations from formulation to clinical application

Illustration highlighting the developmental pathway of natural biopolymer-based nanoformulations, from material selection and formulation optimization to preclinical evaluation and clinical translation. Stages shown: Polymer selection Nano-engineering In vitro evaluation In vivo arthritis models Regulatory and clinical considerations

8. Future Perspectives

Future research is expected to focus on stimuli-responsive nanoformulations, gene-based therapies, and personalized medicine approaches. Integration of advanced fabrication techniques, computational modeling, and translational research strategies may further enhance the clinical potential of natural biopolymer-based nanoformulations for arthritis management[16-17].

9. Conclusion

Natural biopolymer-based nano formulations represent a promising and biologically compatible approach for improving arthritis therapy. Their ability to enable targeted drug delivery, sustained release, and reduced systemic toxicity offers significant advantages over conventional dosage forms. Continued interdisciplinary research and translational efforts are required to fully realize their clinical potential.

DECLARATIONS

Funding

The authors declare that no specific funding was received for this work from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Ethical Approval

This article does not contain any studies involving human participants or animals performed by any of the authors.

Informed Consent

Not applicable.

Author Contributions

All authors contributed equally to the conception, design, literature review, drafting, and revision of the manuscript. All authors have read and approved the final version of the manuscript.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgements

The authors acknowledge the support provided by their respective institutions and colleagues in the completion of this work.

Consent for Publication

All authors have reviewed and approved the manuscript and consent to its publication.

Plagiarism Statement

The authors confirm that this manuscript is original, has not been published previously, and is not under consideration for publication elsewhere.

References

1. Firestein GS. Evolving concepts of rheumatoid arthritis. *Nature*. 2003;423:356–361. DOI: https://doi.org/10.1038/nature01661
2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. *Lancet*. 2016;388(10055):2023–2038. DOI: https://doi.org/10.1016/S0140-6736(16)30173-8
3. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol*. 2015;33:941–951. DOI: https://doi.org/10.1038/nbt.3330
4. Jayakumar R, Prabaharan M, Sudheesh Kumar PT, Nair SV, Tamura H. Biomaterials based on chitin and chitosan in wound dressing applications. *Prog Polym Sci*. 2011;36:961–986. DOI: https://doi.org/10.1016/j.progpolymsci.2011.01.007
5. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med*. 2011;365:2205–2219. DOI: https://doi.org/10.1056/NEJMra1004965
6. Lu HD, Zhao HQ, Wang K, Lv LL. Novel hyaluronic acid–chitosan nanoparticles as non-viral gene delivery vectors targeting osteoarthritis. *Int J Pharm*. 2011;420:358–365. DOI: https://doi.org/10.1016/j.ijpharm.2011.08.046
7. Wang Q, Jiang H, Li Y, Chen W, Li H. Targeted delivery of therapeutics to inflammatory joints using nanotechnology. *Adv Drug Deliv Rev*. 2021;168:64–89. DOI: https://doi.org/10.1016/j.addr.2020.10.012
8. Detsi A, Kavetsou E, Kostopoulou I, et al. Chitosan-based nanoparticles for drug delivery in rheumatoid arthritis. *Pharmaceutics*.

2020;12:669. DOI: https://doi.org/10.3390/pharmaceutics12070669

9. Kumar V, Leekha A, Tyagi A, Kaul A, Mishra AK. Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis. *Pharm Res*. 2017;34:1289–1302. DOI: https://doi.org/10.1007/s11095-016-2094-y
10. Valachová K, Šoltés L. Progress in hyaluronan-based nanoencapsulation systems for drug delivery. *Molecules*. 2025;30:3883. DOI: https://doi.org/10.3390/molecules30193883
11. Manivong S, De Sousa I, Rousseau C, et al. Chitosan-based nanogels for intra-articular drug delivery. *Nanomaterials*. 2022;12:1337. DOI: https://doi.org/10.3390/nano12081337
12. Chen J, Li Y, Wang S, et al. Alginate-based microspheres for sustained intra-articular drug delivery in osteoarthritis. *J Orthop Surg Res*. 2025;20:98. DOI: https://doi.org/10.1186/s13018-025-05698-z
13. Fazal T, Murtaza BN, Shah M, Iqbal S, Rehman M. Recent developments in natural biopolymer-based drug delivery systems. *RSC Adv*. 2023;13:19845–19867. DOI: https://doi.org/10.1039/D3RA03369D
14. Zhang Y, Liu X, Wang Y, et al. Natural polymer-based nanoformulations for osteoarthritis therapy. *Biomaterials Translational*. 2025. DOI: https://doi.org/10.1007/s42242-025-00301-6
15. Durmaz N, Yildiz A, Gursoy RN. pH-sensitive hyaluronic acid–chitosan nanoparticles for rheumatoid arthritis therapy. *J Drug Deliv Sci Technol*. 2025;92:105064. DOI: https://doi.org/10.1016/j.jddst.2025.105064
16. Park K. Facing the truth about nanotechnology in drug delivery. *J Control Release*. 2014;190:3–8. DOI: https://doi.org/10.1016/j.jconrel.2014.05.001
17. Hussain CM, Keçili R. Advanced nanomaterials for biomedical applications. *Adv Colloid Interface Sci*. 2023;309:102791. DOI: https://doi.org/10.1016/j.cis.2022.102791